REG - OptiBiotix Health - Large Order and Record Early Orders for 2026

OptiBiotix HealthAnnouncement

Wed 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260121:nRSU6737Pa&default-theme=true

RNS Number : 6737P  OptiBiotix Health PLC  21 January 2026

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

Large order and Record Early Orders for 2026

 

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business
developing products which reduce hunger and food cravings, enhance the gut
microbiome, and sweet fibres as healthy sugar substitutes, announces that it
has received four orders totalling twenty-four metric tonnes (24mt) of
SlimBiome from Meelung Trading, Taiwan ("Meelung"). These orders will be
delivered at approximately three-month intervals throughout 2026 when they
will be recorded in the Company's management accounts and reported for the 12
months ended 31 December 2026 ("FY2026").

 

Meelung started trading in 1949 as a pharmaceutical company before expanding
into nutraceuticals in 1992 to exploit the growing market opportunity. It
describes itself as one of the most important nutritional supplement
distributors in Taiwan with a focus on patented, branded products with
clinical studies. OptiBiotix signed an agreement with Meelung in June 2025 and
has seen rapid sales growth with regular recurring orders of increasing
size.

 

These orders reflect a growing confidence in SlimBiome and a growing trend
with an increasing number of partners placing orders for FY2026 to secure
supply. This enables OptiBiotix to plan ahead and consolidate multiple orders,
allowing it to negotiate preferential pricing with suppliers and reduce cost.
The Company gains flexibility to pass on any cost savings to partners for
larger orders while maintaining or improving margins, supporting increased
sales growth.

 

This approach has delivered a record start to FY2026, with over £800K in
orders secured from four partners. These will be delivered at various point
throughout FY2026 when they will be recorded and reported in the Company's
FY2026 accounts. These are confirmed orders with a no cancellation clause and
includes the low six figure order received in November 2025 from a well-known
weight management company (RNS: 17 November 2025) planned for delivery and
launch in H1 2026, the Meelung orders, and two other partners.

 

These confirmed orders reflect the growing interest in ingredients like
SlimBiome which support hunger control and appetite reduction similar to the
anti-obesity drugs.  This alternative GLP1 market is new and fast evolving
and estimated to be worth $1.2 billion in 2024 and projected to reach $4.8
billion by 2033, growing at a compound annual growth rate of 16.7% (Market
Intelo, 2024) see  GLP-1 Support Supplements Market Research Report 2033
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fmarketintelo.com%2Freport%2Fglp-1-support-supplements-market%23%3A~%3Atext%3DAs%2520per%2520our%2520latest%2520market%2520intelligence%252C%2520the%2Cgrowing%2520at%2520a%2520robust%2520CAGR%2520of%252016.7%2525.&data=05%7C02%7Cspohara%40optibiotix.com%7C2f368f0bfdf143701cb308de56e49ba5%7Cfd9d39470fcc410da8d30ce1bec67dce%7C1%7C0%7C639043737337058963%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=ADdnFffSHrHncfCAD3OpUBrxRRhZGEkRowZjuWqKos8%3D&reserved=0)
. SlimBiome, with its four clinical studies, international awards, and 'on
pack health claims' is well positioned to exploit this opportunity.

 

Stephen O'Hara, CEO of OptiBiotix Health plc said: "We are pleased to announce
this large order from Meelung as well as record orders for the start of
2026.  To have already secured orders totalling over £800k before the end of
our first month of the year puts us in a strong position for the year ahead.
These orders reflect the growing interest in bringing patented, branded
ingredients, with human studies demonstrating hunger and appetite reduction to
the fast growing 'natural alternative to GLP1' market.

 

The Company intends to provide a trading update for the financial year 2025
once figures have been finalised which will show another year of continued
strong growth. With the start that we've had so far for 2026, the Company is
in the strongest position it has been in with its first-generation products
whilst having overcome a number of challenges with partners on large scale
production (>100,000 mt) of our second-generation products as we move these
along the pathway to launch."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

Engage with the OptiBiotix management team directly by asking questions,
watching video summaries and seeing what other shareholders have to say.

View the full announcement and submit questions to management via our
website:  https://optibiotix.com/link/Pm5WaP
(https://optibiotix.com/link/Pm5WaP)

Subscribe to the new website to get regular updates here:
 https://optibiotix.com/auth/signup
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Foptibiotix.com%2Fauth%2Fsignup&data=05%7C02%7Cspohara%40optibiotix.com%7C91251d27127c43db20c508de57448a9a%7Cfd9d39470fcc410da8d30ce1bec67dce%7C1%7C0%7C639044149066800254%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=bMsfO71mP5serbXOxQMmWA7o1XH%2FFaubVvkQiwIrc3c%3D&reserved=0)

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD and Broker)                     Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has
developed a range of technologies and commercialised products which modulate
the human microbiome to help prevent and manage human disease.  Since the
Group's inception it has created a wide range of microbiome-based ingredients
and products including prebiotic products like SlimBiome®, WellBiome®,
SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc
(OPTI) business, but also skincare through its holdings in SkinBioTherapeutics
PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies
create a diverse portfolio of technologies and products in an emerging area of
healthcare that is of growing interest in consumer markets throughout the
world.

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be,
forward-looking statements. Forward-looking statements are identified by
their use of terms and phrases such as ''believe'', ''could'', "should"
''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'',
"expect", ''will'' or the negative of those, variations or comparable
expressions, including references to assumptions.  These forward-looking
statements are not based on historical facts but rather on the Directors'
current expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof), competitive
advantages, business prospects and opportunities. Such forward-looking
statements reflect the Directors' current beliefs and assumptions and are
based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTURRWRNBUAUAR



            Copyright 2019 Regulatory News Service, all rights reserved